Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims are supported by the provided label excerpts (e.g., doxycycline active ingredient, modified-release bead formulation, and photosensitivity). However, key label content needed to validate dosing/administration and the exact labeled indication wording is missing (Indications and Dosage sections are empty). Several safety/side-effect and counseling claims are only partially supported or not supported by the provided excerpts.
Category Scores
Accurate Statements
Oracea’s active drug is doxycycline.
11 DESCRIPTION (ORACEA (doxycycline, USP) Capsules 40 mg)
Oracea uses a modified-release capsule formulation of doxycycline.
11 DESCRIPTION (two types of doxycycline beads: 30 mg immediate release and 10 mg delayed release)
Because Oracea contains doxycycline, it may cause photosensitivity (increased sensitivity to sunlight) as a side effect.
5.5 Photosensitivity (exaggerated sunburn reaction; minimize/avoid sunlight while using ORACEA)
Unsupported Statements
Because Oracea contains doxycycline, it may cause stomach upset as a side effect.
No stomach upset/GI adverse reaction claim is supported by the provided label excerpts.
Generic doxycycline products may exist.
No statements about generics/availability are present in the provided label excerpts.
Contradictions
Important Omissions
Exact labeled indication language for rosacea (1 INDICATIONS AND USAGE is empty in the provided excerpt), limiting confirmation of whether the label explicitly uses terms like 'persistent' and the exact patient population wording.
Importance:
Moderate
Dosage and administration details (2 DOSAGE AND ADMINISTRATION is empty), meaning claims about prescriber-set schedule and 'typically once daily' cannot be validated against the provided label.
Importance:
High
Any boxed warning content and full warnings/precautions content cannot be assessed because the provided excerpt does not include them (and warnings are incomplete).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/partially supported statements include 'stomach upset' and generalized counseling phrasing. Major missing dosing/administration content prevents validation of frequency/scheduling claims, which could affect safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Dosing/administration claims and some safety/counseling statements are not verifiable because the provided label excerpt lacks the Dosage and Administration section and does not include full adverse reactions/counseling wording.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label excerpts (e.g., photosensitivity, doxycycline active ingredient, modified-release bead description) and avoid asserting dosing frequency/schedule or specific side effects unless the corresponding label text is included.